{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T20:43:33Z","timestamp":1786221813637,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jns.2026.126105","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:04:25Z","timestamp":1784732665000},"page":"126105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Rituximab in AChR and MusK Myasthenia Gravis: long-term follow-up with different therapeutic protocols"],"prefix":"10.1016","volume":"489","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8180-2942","authenticated-orcid":false,"given":"C.","family":"Erra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4862-4165","authenticated-orcid":false,"given":"D.","family":"Ricciardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8912-3055","authenticated-orcid":false,"given":"G.","family":"Abbadessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Tuccillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"De Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Matrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Vinciguerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fasolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Habetswallner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2026.126105_bb0005","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1474-4422(21)00357-4","article-title":"Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders","volume":"21","author":"Huijbers","year":"2022","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.jns.2026.126105_bb0010","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.jns.2026.126105_bb0015","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2026.126105_bb0020","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.pharmthera.2006.03.005","article-title":"B cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target","volume":"112","author":"Dalakas","year":"2001","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jns.2026.126105_bb0025","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/intimm\/dxv038","article-title":"The expanding family of regulatory B cells","volume":"27","author":"Mauri","year":"2015","journal-title":"Int. Immunol."},{"key":"10.1016\/j.jns.2026.126105_bb0030","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/ncpneuro0901","article-title":"B cells as therapeutic targets in autoimmune neurological disorders","volume":"4","author":"Dalakas","year":"2008","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"10.1016\/j.jns.2026.126105_bb0035","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s13311-022-01196-w","article-title":"Evolution of anti-B-cell therapeutics in autoimmune neurological diseases","volume":"19","author":"Stathopoulos","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jns.2026.126105_bb0040","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.immuni.2007.01.009","article-title":"Autoreactivity in human IgG+ memory B cells","volume":"26","author":"Tiller","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.jns.2026.126105_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00613","article-title":"Long-lasting rituximab-induced reduction of specific-but not total-IgG4 in MuSK-positive myasthenia gravis","volume":"11","author":"Marino","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jns.2026.126105_bb0050","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/mus.25973","article-title":"B cells in the pathophysiology of myasthenia gravis","volume":"57","author":"Yi","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2026.126105_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.686466","article-title":"Short- and long-lived autoantibody-secreting cells in autoimmune neurological disorders","volume":"12","author":"Zografou","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jns.2026.126105_bb0060","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaneurol.2016.4190","article-title":"Durability of the rituximab response in acetylcholine receptor autoantibody-positive myasthenia gravis","volume":"74","author":"Robeson","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2026.126105_bb0065","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jneuroim.2008.04.039","article-title":"Sustained response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients","volume":"201-202","author":"Illa","year":"2008","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jns.2026.126105_bb0070","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"D\u00edaz-Manera","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2026.126105_bb0075","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1136\/jnnp-2012-303664","article-title":"Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients","volume":"84","author":"Keung","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2026.126105_bb0080","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: a systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2026.126105_bb0085","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1212\/WNL.55.7.1062-a","article-title":"Rituximab for myasthenia gravis developing after bone marrow transplant","volume":"55","author":"Zaja","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2026.126105_bb0090","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/mus.23412","article-title":"Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study","volume":"46","author":"Collongues","year":"2012","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2026.126105_bb0095","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-Musk myasthenia gravis: multicenter blinded prospective review","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2026.126105_bb0100","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/mus.26156","article-title":"Rituximab in refractory myasthenia gravis: extended prospective study results","volume":"58","author":"Beecher","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2026.126105_bb0105","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/1756285611411503","article-title":"Response of patients with refractory myasthenia gravis to rituximab: a retrospective study","volume":"4","author":"Nowak","year":"2011","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.jns.2026.126105_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1275533","article-title":"Rituximab treatment in myasthenia gravis","volume":"14","author":"Vesperinas-Castro","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jns.2026.126105_bb0115","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","article-title":"Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis","volume":"262","author":"Iorio","year":"2015","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2026.126105_bb0120","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1136\/jnnp-2019-322606","article-title":"Rituximab in AChR subtype of myasthenia gravis: systematic review","volume":"9","author":"Di Stefano","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2026.126105_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.736190","article-title":"Effectiveness and safety of rituximab for refractory myasthenia gravis: a systematic review and single-arm meta-analysis","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jns.2026.126105_bb0130","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jocn.2020.11.043","article-title":"Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: a meta-analysis","volume":"85","author":"Li","year":"2021","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.jns.2026.126105_bb0135","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.725700","article-title":"Efficacy and safety of immunotherapies in refractory myasthenia gravis: a systematic review and Meta-analysis","volume":"12","author":"Feng","year":"2021","journal-title":"Front. Neurol."},{"issue":"98","key":"10.1016\/j.jns.2026.126105_bb0140","first-page":"e376","article-title":"Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG study","volume":"25","author":"Nowak","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2026.126105_bb0145","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and safety of rituximab for new-onset generalized myasthenia gravis the RINOMAX randomized clinical trial","volume":"79","author":"Piehl","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2026.126105_bb0150","article-title":"Rituximab for myasthenia gravis","volume":"7","author":"Dodd","year":"2025","journal-title":"Cochrane Database Syst. Rev."},{"issue":"11","key":"10.1016\/j.jns.2026.126105_bb0155","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70418","article-title":"Rituximab in new-onset generalized myasthenia gravis: long-term follow-up of the RINOMAX clinical trial","volume":"32","author":"Wu","year":"2025","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2026.126105_bb0160","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for Management of Myasthenia Gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2026.126105_bb0165","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231213240","article-title":"Guideline for the management of myasthenic syndromes","volume":"16","author":"Wiendl","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.jns.2026.126105_bb0170","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"(2021) safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2026.126105_bb0175","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2026","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2026.126105_bb0180","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2026.126105_bb0185","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/mus.28044","article-title":"Efficacy of ravulizumab in patients with generalized myasthenia gravis by time from diagnosis: a post hoc subgroup analysis of the CHAMPION MG study","volume":"69","author":"Howard","year":"2024","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2026.126105_bb0190","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2026.126105_bb0195","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1056\/NEJMoa2501561","article-title":"A phase 3 trial of Inebilizumab in generalized myasthenia gravis","volume":"392","author":"Nowak","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2026.126105_bb0200","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00415-025-13161-6","article-title":"Monitoring anti-rituximab antibodies in myasthenia gravis affects the time to event during rituximab treatment","volume":"272","author":"H\u00e9raud","year":"2025","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2026.126105_bb0205","doi-asserted-by":"crossref","first-page":"7219","DOI":"10.1038\/s41598-025-90937-w","article-title":"Efficacy and safety of rituximab in anti-MuSK myasthenia gravis: a systematic review and meta-analysis","volume":"15","author":"Chayanopparat","year":"2025","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.jns.2026.126105_bb0210","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1212\/01.wnl.0000228225.23349.5d","article-title":"Et Al (2006) anti-MuSK antibodies: correlation with myasthenia gravis severity","volume":"67","author":"Bartoccioni","year":"2006","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jns.2026.126105_bb0215","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/mus.23944","article-title":"Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis?","volume":"49","author":"Sanders","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2026.126105_bb0220","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1506845","article-title":"Exploring the clinical significance of anti-acetylcholine receptor antibody titers, changes, and change rates in myasthenia gravis","volume":"15","author":"Luo","year":"2025","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jns.2026.126105_bb0225","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jneuroim.2017.05.021","article-title":"Responsiveness to low- dose rituximab in refractory generalized myasthenia gravis","volume":"311","author":"Jing","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jns.2026.126105_bb0230","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jamaneurol.2020.0851","article-title":"Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis","volume":"77","author":"Brauner","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2026.126105_bb0235","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40199-025-00557-y","article-title":"Efficacy and safety of different dosages of rituximab for myasthenia gravis: a single-arm meta-analysis","volume":"33","author":"Li","year":"2025","journal-title":"Daru"},{"key":"10.1016\/j.jns.2026.126105_bb0240","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1439899","article-title":"Efficacy and safety of low-dose rituximab in the treatment of myasthenia gravis: a systemic review and meta-analysis","volume":"15","author":"Yang","year":"2024","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jns.2026.126105_bb0245","article-title":"A pilot study of the immunological profile and efficacy of rituximab in muscle-specific kinase antibody-positive myasthenia gravis","volume":"16","author":"Li","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jns.2026.126105_bb0250","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.nmd.2016.12.004","article-title":"Resistant myasthenia gravis and rituximab: a monocentric retrospective study of 28 patients","volume":"27","author":"Afanasiev","year":"2017","journal-title":"Neuromuscul. Disord."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26003874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26003874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T20:09:08Z","timestamp":1786219748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X26003874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":50,"alternative-id":["S0022510X26003874"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2026.126105","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab in AChR and MusK Myasthenia Gravis: long-term follow-up with different therapeutic protocols","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2026.126105","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"126105"}}